U.S., Sept. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07172256) titled 'CUE-101with Pembrolizumab for LA-HPV+HNSCCs' on Sept. 03.
Brief Summary: This is a phase 2, pilot, randomized, open-label 3-arm study to assess the safety, tolerability, and efficacy of CUE-101 monotherapy, and CUE-101 in combination with pembrolizumab as neoadjuvant therapy in HLA-A*0201-positive treatment naive participants with locally advanced, unresectable HPV-16 associated head and neck squamous cell carcinoma (HNSCC).
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Head and Neck Squamous Cell Carcinoma
HPV Positive Oropharyngeal Squamous Cell Carcinoma
New Diagnosis Tumor
Locally Advanced
Intervention...